ORGOVYX (relugolix), the First FDA-Approved Oral Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist for Advanced Prostate Cancer, Available at Biologics by McKesson

January 21, 2021

CARY, N.C., Jan. 21, 2021 Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by Myovant Sciences as a specialty pharmacy provider for ORGOVYXTM (relugolix) for the treatment of advanced prostate cancer.

ORGOVYX, approved by the U.S. Food and Drug Administration (FDA) on December 18, 2020, is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist that blocks the GnRH receptor and reduces production of testicular testosterone, a hormone known to stimulate the growth of prostate cancer. ORGOVYX was approved through the FDA’s Priority Review pathway, which is granted to drugs that are expected to have a large impact on a disease’s treatment.

“We are pleased to provide this new prostate cancer therapy with demonstrated robust efficacy and safety, all in one daily pill,” said Ashleigh Burdette, senior director of Clinical Innovation at Biologics. “The COVID-19 pandemic has highlighted the importance of oral treatments for patients, especially those who may experience difficulties and risks associated with traveling to receive treatments.”

Biologics specialty pharmacy is committed to and recognized for its level of customer service as well as its innovative, high-touch and multidisciplinary patient-centric approach. Each team includes pharmacists with in-depth knowledge of therapies, experienced nurses, and financial counselors who are familiar with various financial assistance programs and organizations that help patients. This deeply skilled care team works together to develop individualized care plans that address each patient’s unique clinical, financial and emotional needs and streamlines communication back to the treating provider, enabling high-quality care and differentiated outcomes. In addition, the Biologics team works closely with payers to ensure patients can access the specialty medications they need.

Physicians may submit prescriptions to Biologics via phone (800.850.4306), fax (800.823.4506) or eScribe. For electronic prescribing systems, physicians may search for Biologics within their EMR system.

About Biologics by McKesson

Biologics by McKesson is an independent specialty pharmacy with more than 25 years of experience connecting patients to life-changing medications in oncology and other rare and complex therapeutic areas. Built on the foundation of deep clinical expertise and a high-touch approach to patient care, Biologics delivers seamless access and personalized engagement, so patients get the most out of the care they receive. As a business within McKesson Corporation, Biologics harnesses unparalleled reach and connectivity across the healthcare system to connect the dots between payers, providers and biopharma, so together, they can deliver better care and outcomes for every patient.

Public Relations Contact